Finally, outstanding results have been reported with new immunotherapies with anti-CD19 CAR-T [8,12], which led to the approval of brexucabtagene autoleucel as salvage therapy for R/R MCL patients. This evidence concerns the gene CD19 and mantle cell lymphoma.